# Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

> **NCT05657301** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Origen Biotechnology Co., Ltd.** · enrollment: 25 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** KH631

## Key facts

- **NCT ID:** NCT05657301
- **Lead sponsor:** Chengdu Origen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657301, "Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05657301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*